Home › Trials › NCT06856343

Observational study on Olaparib treatment for early breast cancer in France

REBECCA Real-world Early BrEast CanCer mAnagement REBECCA. a French National Multicentric Real-world Study of Early Breast Cancer Patients

Observational AstraZeneca · NCT06856343

This study is looking at how well patients with early HER2-negative breast cancer in France stick to their Olaparib treatment and what their outcomes are.

Quick facts

Study typeObservational
Enrollment126 (estimated)
Ages18 Years and up
SexAll
SponsorAstraZeneca Industry-sponsored
Locations58 sites (Clermont-Ferrand, Auvergne-Rh ne-Alpes and 57 other locations)
Trial IDNCT06856343 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate the completion rates of adjuvant Olaparib treatment among patients with HER2-negative early breast cancer in France. It involves a multicenter prospective cohort of patients who are about to start treatment at their physician's discretion. The study will collect data on patient outcomes and treatment adherence to better understand the real-world effectiveness of Olaparib in this population.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older diagnosed with HER2-negative early breast cancer who are about to begin adjuvant Olaparib treatment.

Not a fit: Patients who do not consent to participate or are enrolled in the Early Access Program may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide insights into the effectiveness and adherence to Olaparib treatment, potentially improving management strategies for early breast cancer patients.

How similar studies have performed: While this study focuses on a specific treatment in a real-world setting, similar observational studies have shown success in evaluating treatment adherence and outcomes in cancer care.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Male or female aged ≥ 18 years
* Patient diagnosed with HER2-negative eBC
* Patient about to be initiated with adjuvant Olaparib at their physician's discretion
* Patient has been informed and does not object to participation in the study.

Exclusion Criteria:

* Patient not consenting to participate.
* Patients included in the Early Access Program

Where this trial is running

Clermont-Ferrand, Auvergne-Rh ne-Alpes and 57 other locations

+8 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Breast Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.